Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety and PK Study of E2086 in Healthy Adults and Elderly
NCT05745207Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of E2086 in narcolepsy type 1 (NT1), sponsored by Eisai Co., Ltd. Primary endpoints: Treatment-emergent Adverse Events, Serious Adverse Events and 7 more. Started Feb 2023; status: completed.
02
Drugs
E2086
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT05745207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05745207.